Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
N/A Completed N=105 Randomized Single-blind Treatment

rTMS for MDD: 5.5cm Rule vs. F3 Targeting

Major Depressive Disorder · Depression
Source: ClinicalTrials.gov NCT03378570 ↗
Enrolled (actual)
105
Serious AEs
0.0%
Results posted
Feb 2025
Primary outcomePrimary: Percentage Change in Patient Health Questionnaire 9-Item Assessment Score — -38.7; -39.1 percentage of change from baseline — p=0.945

Summary

The purpose of this study is to examine the effects of different treatment locations using repetitive transcranial magnetic stimulation (rTMS) to treat major depressive disorder.

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage Change in Patient Health Questionnaire 9-Item Assessment Score		 -38.7; -39.1 0.945
PRIMARY
Percentage Change in Montgomery-Asberg Depression Rating Scale Score		 -39.5; -37.8 0.828
PRIMARY
Percentage Change in General Anxiety Disorder 7-Item Assessment Score		 -33.6; 27.5 0.252
PRIMARY
Response and Remission Rates on Patient Health Questionnaire 9-Item Assessment		 36.6; 43.4; 22.0; 20.8 0.505
PRIMARY
Response and Remission Rates on Montgomery-Asberg Depression Rating Scale		 43.3; 43.2; 20.0; 18.9 0.994
PRIMARY
Response Rates on General Anxiety Disorder 7-Item Assessment		 27.3; 30.2 0.778
SECONDARY
Montreal Cognitive Assessment Score Changes		 .59; .56 .951
SECONDARY
Emotion Measures		 -7.2; -10.4; -2.7; -9.2; -4.5; -6.7 .278

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of major depressive disorder
  • Age between 18 and 90 years
  • rTMS is clinically indicated as determined by clinical rTMS physician team at University of Iowa

Exclusion Criteria

  • rTMS contraindication such as implanted ferromagnetic material in the head or history of epilepsy with poorly controlled seizures
  • MRI exclusion criteria (if participating in MRI portion of study) including implanted device such as:
  • Pacemaker
  • Coronary Stent
  • Defibrillator
  • Neurostimulation
  • Or any of the following conditions:
  • Claustrophobia
  • Uncontrolled high blood pressure
  • Poorly controlled atrial fibrillation
  • Significant heart disease
  • Hemodynamic instability
  • Severe kidney disease
  • Pregnant, trying to become pregnant, or breast feeding
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03378570). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search